A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

NCT05744401 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
197
Enrollment
INDUSTRY
Sponsor class

Stopped Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.

Conditions

Interventions

Sponsor

Alector Inc.

Collaborators